Your browser doesn't support javascript.
loading
The effects of inulin-type fructans on cardiovascular disease risk factors: systematic review and meta-analysis of randomized controlled trials.
Talukdar, Jhalok Ronjan; Cooper, Matthew; Lyutvyn, Lyuba; Zeraatkar, Dena; Ali, Rahim; Berbrier, Rachel; Janes, Sabrina; Ha, Vanessa; Darling, Pauline B; Xue, Mike; Chu, Alexandro; Chowdhury, Fariha; Harnack, Hope E; Huang, Louise; Malik, Mikail; Powless, Jacqui; Lavergne, Florence V; Zhang, Xuehong; Ehrlich, Shelley; Jenkins, David Ja; Sievenpiper, John L; Banfield, Laura; Mbuagbaw, Lawrence; de Souza, Russell J.
Afiliação
  • Talukdar JR; Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.
  • Cooper M; Department of Medicine, University of Alberta, Edmonton, AB, Canada.
  • Lyutvyn L; Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.
  • Zeraatkar D; Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada; Blavatnik Institute, Harvard Medical School, Boston, MA, United States.
  • Ali R; Faculty of Law, Common Law Section, University of Ottawa, Ottawa, ON, Canada.
  • Berbrier R; Division of Dermatology, McGill University Health Centre, Montreal, QC, Canada.
  • Janes S; Li Ka Shing Knowledge Institute, St. Michael's Hospital, Unity Health Toronto, Toronto, ON, Canada.
  • Ha V; School of Medicine, Faculty of Health Sciences, Queen's University, Kingston, ON, Canada.
  • Darling PB; School of Nutrition Sciences, University of Ottawa, Ottawa, ON, Canada.
  • Xue M; Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada.
  • Chu A; Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada.
  • Chowdhury F; Department of Rehabilitation Science(s), McMaster University, Hamilton, ON, Canada.
  • Harnack HE; Department of Kinesiology, Faculty of Science, McMaster University, Hamilton, ON, Canada.
  • Huang L; Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada.
  • Malik M; Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada.
  • Powless J; Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.
  • Lavergne FV; School of Nutrition Sciences, Faculty of Health Sciences, University of Ottawa, ON, Canada.
  • Zhang X; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, United States.
  • Ehrlich S; Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
  • Jenkins DJ; Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital, Toronto, ON, Canada; Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON, Canada; Department of Nutritional Sciences, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada; Department o
  • Sievenpiper JL; Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital, Toronto, ON, Canada; Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON, Canada; Department of Nutritional Sciences, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada; Department o
  • Banfield L; Health Sciences Library, McMaster University, Hamilton, ON, Canada; Global Health Graduate Program, McMaster University, Hamilton, ON, Canada.
  • Mbuagbaw L; Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada; Department of Anesthesia, McMaster University, Hamilton, ON, Canada; Department of Pediatrics, McMaster University, Hamilton, ON, Canada; Biostatistics Unit, Father Sean O'Sullivan Research Centre
  • de Souza RJ; Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada; Toronto 3D Knowledge Synthesis and Clinical Trials Unit, St. Michael's Hospital, Toronto, ON, Canada; Global Health Graduate Program, McMaster University, Hamilton, ON, Canada; Department of Pedia
Am J Clin Nutr ; 119(2): 496-510, 2024 02.
Article em En | MEDLINE | ID: mdl-38309832
ABSTRACT

BACKGROUND:

Inulin-type fructans (ITF) are the leading prebiotics in the market. Available evidence provides conflicting results regarding the beneficial effects of ITF on cardiovascular disease risk factors.

OBJECTIVES:

This study aimed to evaluate the effects of ITF supplementation on cardiovascular disease risk factors in adults.

METHODS:

We searched MEDLINE, EMBASE, Emcare, AMED, CINAHL, and the Cochrane Library databases from inception through May 15, 2022. Eligible randomized controlled trials (RCTs) administered ITF or placebo (for example, control, foods, diets) to adults for ≥2 weeks and reported one or more of the following low, very-low, or high-density lipoprotein cholesterol (LDL-C, VLDL-C, HDL-C); total cholesterol; apolipoprotein A1 or B; triglycerides; fasting blood glucose; body mass index; body weight; waist circumference; waist-to-hip ratio; systolic or diastolic blood pressure; or hemoglobin A1c. Two reviewers independently and in duplicate screened studies, extracted data, and assessed risk of bias. We pooled data using random-effects model, and assessed the certainty of evidence (CoE) using the Grading of Recommendations, Assessment, Development and Evaluation approach.

RESULTS:

We identified 1767 studies and included 55 RCTs with 2518 participants in meta-analyses. The pooled estimate showed that ITF supplementation reduced LDL-C [mean difference (MD) -0.14 mmol/L, 95% confidence interval (95% CI -0.24, -0.05), 38 RCTs, 1879 participants, very low CoE], triglycerides (MD -0.06 mmol/L, 95% CI -0.12, -0.01, 40 RCTs, 1732 participants, low CoE), and body weight (MD -0.97 kg, 95% CI -1.28, -0.66, 36 RCTs, 1672 participants, low CoE) but little to no significant effect on other cardiovascular disease risk factors. The effects were larger when study duration was ≥6 weeks and in pre-obese and obese participants.

CONCLUSION:

ITF may reduce low-density lipoprotein, triglycerides, and body weight. However, due to low to very low CoE, further well-designed and executed trials are needed to confirm these effects. PROSPERO REGISTRATION NUMBER CRD42019136745.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limite: Adult / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limite: Adult / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article